uniQure N.V. Files BLA and UK MAA for AMT-130 (Huntington's Disease)

What Happened
uniQure N.V. announced on September 2, 2026 that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130) to treat Huntington’s disease, and also submitted a Marketing Authorisation Application (MAA) to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for the same therapy. The announcement was furnished as a press release (Exhibit 99.1) in the company’s Form 8‑K (Item 7.01).

Key Details

• Date of disclosure: September 2, 2026 (Form 8‑K, Item 7.01, Regulation FD disclosure).
• Product: ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington’s disease.
• Regulatory filings: BLA submitted to the U.S. FDA seeking accelerated approval; MAA submitted to the U.K. MHRA.
• Press release furnished as Exhibit 99.1 to the 8‑K; report signed by Jeannette Potts, Chief Legal and Compliance Officer.

Why It Matters
These regulatory submissions are material development milestones for uniQure because they move AMT‑130 from clinical/regulatory stages toward potential market authorization in major markets (U.S. and U.K.). For investors, submission of a BLA and MAA can affect the company’s near‑term news flow, perceived regulatory risk, and long‑term commercial prospects if approvals are granted. The filing itself is a public disclosure (Regulation FD) of these actions; approval decisions, timelines, and potential financial impact will depend on regulatory review outcomes.